Kaiser Permanente Health Plan of Mid-Atlantic States, Inc. (Tremfya) , Skyrizi (risankizumab), Taltz (), Siliq (), Ilumya () Prior Authorization (PA) Pharmacy Benefits Prior Authorization Help Desk Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions: This form is used by Kaiser Permanente and/or participating providers for coverage of (Tremfya) guselkumab, Skyrizi (risankizumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab) . Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331- 2103. Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html

1 – Patient Information

Patient Name: ______Kaiser Medical ID#: ______Date of Birth: ______

2 – Prescriber Information

Is the prescriber a Rheumatologist or Dermatologist? □ No □ Yes

If consulted with a specialist, specialist name and specialty: ______

Prescriber Name: ______Specialty: ______NPI: ______

Prescriber Address: ______

Prescriber Phone #: ______Prescriber Fax #: ______

Please check the boxes that apply: □ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: ______Pharmacy NPI: ______

Pharmacy Phone #______Pharmacy Fax #: ______

4 – Drug Therapy Requested Drug 1: Name/Strength/Formulation: ______Sig: ______

Drug 2: Name/Strength/Formulation: ______Sig: ______

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc. Prior Authorization Form Revision date: 7/30/2020 Page 1 of 2

5–Diagnosis/Clinical Criteria Initial Therapy Ankylosing Spondylitis – Taltz only 1. Member has diagnosis of ankylosing spondylitis, AND □ No □ Yes 2. Member has documented inadequate response (of at least 3 month trial), intolerance, or contraindication to BOTH of the following: a. ONE or more tumor necrosis factor (TNF-alpha) inhibitors: (Inflectra, Remicade, Enbrel (etanercept), Humira () b. Cosentyx () □ No □ Yes

Psoriatic Arthritis – Taltz only 1. Member has diagnosis of active , AND □ No □ Yes 2. Member has documented inadequate response (of at least a 3 month trial), intolerance, or contraindication to BOTH of the following: a. ONE or more tumor necrosis factor (TNF alpha) inhibitors: Inflectra or Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab) b. Cosentyx (secukinumab) □ No □ Yes Plaque – Tremfya, Skyrizi, Ilumya, Taltz, Siliq 1. Member has diagnosis of moderate-to-severe plaque psoriasis, AND □ No □ Yes 2. Member meets prior authorization criteria for Cosentyx, AND □ No □ Yes 3. Member has documented inadequate response (of at least 3 month trial), intolerance, or contraindication to Cosentyx (secukinumab) □ No □ Yes 4. For Ilumya, Siliq, Taltz: member must additionally have documentation of inadequate response, intolerance, or contraindication to Tremfya OR Skyrizi AND Stelara for approval. Does member meet this criteria? □ No □ Yes

Continuation of Therapy: 1. Does the patient have a positive clinical response to ? AND □ No □ Yes 2. Has a specialist follow-up occurred in the past 12 months? □ No □ Yes

6 – Prescriber Sign-Off Additional Information – Please provide any additional information that should be taken into consideration: ______

I certify that the information provided is accurate. Supporting documentation is available for State audits. Prescriber Signature: Date:

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc. Prior Authorization Form Revision date: 7/30/2020 Page 2 of 2